Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature

BACKGROUND: Immune checkpoint inhibitor therapy has changed the standard drug therapy for relapsed or advanced non-small cell lung cancer; its efficacy is well-recognized by pulmonary physicians, oncologists, and thoracic surgeons. Nivolumab, one of the anti-programmed cell death 1 antibodies, was t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasegawa, Takeo, Ozaki, Yuki, Inoue, Takuya, Watanabe, Yuzuru, Fukuhara, Mitsuro, Yamaura, Takumi, Muto, Satoshi, Okabe, Naoyuki, Higuchi, Mitsunori, Shio, Yutaka, Suzuki, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813076/
https://www.ncbi.nlm.nih.gov/pubmed/31647029
http://dx.doi.org/10.1186/s13256-019-2245-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813076/
https://www.ncbi.nlm.nih.gov/pubmed/31647029
http://dx.doi.org/10.1186/s13256-019-2245-y

Ejemplares similares